河北医科大学学报

• 论著 • 上一篇    下一篇

阿帕替尼联合化疗用于二线治疗失败晚期卵巢癌的临床观察

  

  1. 1.河北北方学院研究生部，河北 张家口 075000；2.河北北方学院附属第一医院肿瘤内科，河北 张家口 075000
  • 出版日期:2017-12-25 发布日期:2017-12-19
  • 作者简介:李琪（1992-），女，河北定州人，河北北方学院医学硕士研究生，从事肿瘤诊治研究。

Clinical observation of apatinib combined with chemotherapy for secondline treatment failure in advanced ovarian cancer#br#

  1. 1.Hebei North College Graduate Department， Zhangjiakou 075000， China； 2.Department of
    Medical Oncology, the First Affiliated Hospital of Hebei North College， Zhangjiakou 075000， China
  • Online:2017-12-25 Published:2017-12-19

HTML

PDF (PC)

297

摘要： ［摘要］〓
〖HTH〗目的〖HTSS〗〖KG*2〗观察新型靶向药物阿帕替尼联合化疗治疗复发后耐药卵巢癌的近期疗效和安全性。
〖HTH〗方法〖HTSS〗〖KG*2〗选择二线化疗失败的进展期卵巢癌患者30例，按治疗方法分为试验组10例和对照组20例，试验组采用阿帕替尼加紫杉类、蒽环类药物为基础的化疗方案，对照组采用以紫杉类或蒽环类为基础化疗方案化疗，比较2组治疗效果及不良反应发生情况。
〖HTH〗结果〖HTSS〗〖KG*2〗6个周期后试验组临床疗效优于对照组，客观缓解率和疾病控制率高于对照组，差异均有统计学意义（P＜005）。不良反应主要为手足综合征、高血压、胃肠胀气及腹泻等，主要为1~2级。
〖HTH〗结论〖HTSS〗〖KG*2〗阿帕替尼联合化疗治疗复发后耐药卵巢癌有较好的疗效，且不良反应可耐受。

关键词: 卵巢肿瘤, 抗药性, 肿瘤, 阿帕替尼, 药物疗法, 联合

Abstract: ［Abstract］〓Objective〖HTSS〗〓To observe the shortterm efficacy and safety of the new targeted drug apatinib combined with chemotherapy in the treatment of patients with ovarian cancer recurrence.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓A total of 30 cases of patients with secondline treatment failure in advanced ovarian cancer were randomly divided into 2 groups： the observation group(n=10) and the control group(n=20).The patients with advanced ovarian cancer adopted a apatinib and taxel， anthracyclinesbased combination chemotherapy regimen as observation group. Concurrent other patients who did not receive apatinib were chosen as control group. The therapeutic efficacy and sideeffect of the two groups were compare. 
〖HTH〗〖WTHZ〗Results〖HTSS〗〓After 6 cycles, clinical curative effect of observation group is better than the control group. There were significant differences in the objective response rate and the disease control rate(P＜005).The most common adverse reactions were handfoot syndrome, hypertension, flatulence and diarrhea, mainly in grade 1-2.
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Apatinib combined with chemotherapy is an effective and welltolerated treatment for advanced ovarian cancer, and the adverse reaction were tolerable.

Key words: ovarian neoplasms, drug resistance, neoplasm, apatinib, drug therapy, combination

版权所有 © 《河北医科大学学报》编辑部
本系统由北京玛格泰克科技发展有限公司设计开发